- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07951034
A Study of HER2-Targeted Antibody-Drug Conjugates Compared With Hormone-Based Therapy for Hormone Receptor-Positive, HER2-Low Metastatic Breast Cancer
A Phase 3 Randomized Controlled Clinical Study of Anti-HER2 Antibody-Drug Conjugates for Hormone Receptor-Positive/HER2-Low Metastatic Breast Cancer (the Rosy Trial)
This phase 3 study will compare anti-HER2 antibody-drug conjugate treatment with hormone-receptor-directed treatment in women with endocrine therapy-resistant, hormone receptor-positive, HER2-low metastatic breast cancer. Participants are assigned at random in a 1:1 ratio to one of the two treatment groups. The primary objective is to compare progression-free survival. Other planned assessments include overall survival, tumor response, adverse events, and patient-reported quality-of-life and psychological measures. The planned sample size is 288 participants, subject to confirmation against the final approved protocol.
Studienübersicht
Status
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
- Name: Ying Wang
- Telefonnummer: +86 13925038181
- E-Mail: wangy556@mail.sysu.edu.cn
Studienorte
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Adult female, age 18-70 years, with metastatic breast cancer confirmed by pathology or imaging. **The consent form states 18-75 years; confirm the approved age range.**
- Hormone receptor-positive disease (ER ≥1% and/or PR ≥1%) and HER2-low disease (IHC 1+, or IHC 2+ with no amplification by FISH/ISH).
- Prior endocrine therapy failure.
- At least one evaluable target lesion under RECIST 1.1, or osteolytic bone metastases only.
- Stable or asymptomatic brain metastases permitted.
- ECOG performance status ≤2 and life expectancy ≥3 months.
- Prior treatment-related toxicities resolved to CTCAE v5.0 grade ≤1, except alopecia or other toxicity judged safe by the investigator.
- Adequate marrow, hepatic, renal, and cardiac function as specified in the final protocol; the application lists WBC ≥3.0×10^9/L, ANC ≥1.5×10^9/L, platelets ≥70×10^9/L, total bilirubin ≤3×ULN, ALT/AST ≤2.5×ULN (≤5×ULN with liver metastases), serum creatinine ≤1.5×ULN or creatinine clearance ≥60 mL/min, LVEF ≥55%, and QTcF ≤470 ms.
- Able to understand study procedures, provide informed consent, and sign the consent form.
Exclusion Criteria:
- Patients who had received chemotherapy, radiotherapy, immunotherapy, and endocrine therapy for breast cancer within 2 weeks before enrollment.;
- Patients who had performed major surgery within 2 weeks before enrollment.
- Severe heart disease or discomfort within 12 months, including, but not limited to, the following: unstable angina pectoris, myocardial infarction, cerebral hemorrhage and cerebral infarction (except for silent lacunar cerebral infarction without treatment);
- Have active autoimmune diseases (such as corticosteroids or immunosuppressive drugs) requiring systemic treatment in the past 2 years, excluding those with adrenal insufficiency requiring corticosteroid replacement therapy;
- Have a clear history of neurological or mental disorders, including epilepsy or dementia;
- According to the judgment of the researchers, there are some accompanying diseases that seriously endanger the safety of patients or affect patients to complete the study.
- Those who have been known to have allergic history to all study drugs or similar agentss;
- According to the estimation of the investigator , the patient's compliance with the clinical study is insufficient or the researcher believes that there are other factors that are not suitable for the study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Anti-HER2 antibody-drug conjugate treatment.
Participants receive one of the anti-HER2 antibody-drug conjugates (ADCs) permitted by the protocol: DS-8201 and A1811. The assigned ADC is administered according to the approved protocol until objective disease progression, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first. |
Administered once every 21 days (q21d). Add the protocol-approved dose, route, and treatment duration/stop rule. Administered once every 21 days (q21d). Add the protocol-approved dose, route, and treatment duration/stop rule. |
|
Aktiver Komparator: Hormone-receptor-directed treatment (endocrine therapy with or without targeted therapy).
Participants receive endocrine therapy alone or in combination with a targeted therapy, according to the approved protocol. |
Doctors choose endocrine therapy independently |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progression-Free Survival (PFS)
Zeitfenster: 24 months
|
Time from randomization to first documented disease progression or death from any cause. |
24 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Overall Survival (OS)
Zeitfenster: 36 months
|
Time from randomization to death from any cause. |
36 months
|
|
Objective Response Rate (ORR)
Zeitfenster: 12 months
|
Proportion of evaluable participants whose best overall response is complete or partial response per RECIST 1.1. |
12 months
|
|
Disease Control Rate (DCR)
Zeitfenster: 12 months
|
Proportion with complete response, partial response, or stable disease per the approved definition. |
12 months
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Adverse events
Zeitfenster: From the first dose of study treatment to 30 days after the last dose of study treatment.
|
The incidence of adverse events in the two groups will be analyzed and graded according to NCI CTCAE version 5.0. |
From the first dose of study treatment to 30 days after the last dose of study treatment.
|
Mitarbeiter und Ermittler
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Koleva-Kolarova RG, Oktora MP, Robijn AL, Greuter MJW, Reyners AKL, Buskens E, de Bock GH. Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis. Cancer Treat Rev. 2017 Apr;55:16-25. doi: 10.1016/j.ctrv.2017.01.001. Epub 2017 Feb 20.
- Mendes D, Alves C, Afonso N, Cardoso F, Passos-Coelho JL, Costa L, Andrade S, Batel-Marques F. The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review. Breast Cancer Res. 2015 Nov 17;17:140. doi: 10.1186/s13058-015-0648-2.
- Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018 Jul 10;36(20):2105-2122. doi: 10.1200/JCO.2018.77.8738. Epub 2018 May 30.
- Giuliani S, Ciniselli CM, Leonardi E, Polla E, Decarli N, Luchini C, Cantaloni C, Gasperetti F, Cazzolli D, Berlanda G, Bernardi D, Pellegrini M, Triolo R, Ferro A, Verderio P, Barbareschi M. In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases. Virchows Arch. 2016 Jul;469(1):45-50. doi: 10.1007/s00428-016-1940-y. Epub 2016 Apr 21.
- Schalper KA, Kumar S, Hui P, Rimm DL, Gershkovich P. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria. Arch Pathol Lab Med. 2014 Feb;138(2):213-9. doi: 10.5858/arpa.2012-0617-OA. Epub 2013 Oct 28.
- Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, Krop IE, Lee C, Fujisaki Y, Sugihara M, Zhang L, Shahidi J, Takahashi S. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. J Clin Oncol. 2020 Jun 10;38(17):1887-1896. doi: 10.1200/JCO.19.02318. Epub 2020 Feb 14.
- Yao X, Jiang J, Wang X, Huang C, Li D, Xie K, Xu Q, Li H, Li Z, Lou L, Fang J. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity. Breast Cancer Res Treat. 2015 Aug;153(1):123-33. doi: 10.1007/s10549-015-3503-3. Epub 2015 Aug 8.
- Ocana A, Amir E, Pandiella A. HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates. Breast Cancer Res. 2020 Jan 31;22(1):15. doi: 10.1186/s13058-020-1252-7.
- Rios-Doria J, Harper J, Rothstein R, Wetzel L, Chesebrough J, Marrero A, Chen C, Strout P, Mulgrew K, McGlinchey K, Fleming R, Bezabeh B, Meekin J, Stewart D, Kennedy M, Martin P, Buchanan A, Dimasi N, Michelotti E, Hollingsworth R. Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies. Cancer Res. 2017 May 15;77(10):2686-2698. doi: 10.1158/0008-5472.CAN-16-2854. Epub 2017 Mar 10.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- SYSKY-2022-208-07
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .